Benzinga | Apr 28, 2021 04:03PM EDT

Adverum Biotechnologies Provides Update On INFINITY Trial Evaluating ADVM-022 In Patients With Diabetic Macular Edema; Co Says Has Decided To Immediately Unmask INFINITY Phase 2 Study

dverum Biotechnologies, Inc. (NASDAQ:ADVM) announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurred 30 weeks after randomization in one patient treated with a single intravitreal injection of the high dose (6 x 10^11 vg/eye) of ADVM-022 who has developed hypotony, with panuveitis and loss of vision in the treated eye.